Assignment history

Inventors

The named inventors for US Patent 11,123,331 are:

• Robert D. Gordon
• Per Holm
• Anne-Marie Lademann
• Tomas Norling

All inventors were associated with Veloxis Pharmaceuticals Inc. at the time of filing, as indicated by the "Original Assignee" information on the Google Patents page.

Original assignee

The entity named as the original assignee on the issued patent US11123331B2 is Veloxis Pharmaceuticals Inc.

Veloxis Pharmaceuticals Inc. is a pharmaceutical company that develops, manufactures, and commercializes therapies for transplant patients. Their primary line of business is focused on immunosuppressive treatments, with their lead product, Envarsus XR (tacrolimus extended-release tablets), embodying the claims of this patent.

Veloxis Pharmaceuticals Inc. was acquired by Asahi Kasei Pharma Corporation in February 2020. Despite the acquisition, it continues to operate as a subsidiary under the Veloxis name.

Assignment timeline

The USPTO Assignment Center (https://assignmentcenter.uspto.gov/) was searched for patent number US11123331. The following assignment records were found:

• 2021-03-17 (executed) / recorded 2021-03-17 — Reel 057199/0569
  • Conveyance: Assignment of Assignor's Interest
  • Assignor: VELOXIS PHARMACEUTICALS A/S
  • Assignee: VELOXIS PHARMACEUTICALS INC.
  • Correspondent: MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP, ATTN: PATENTS, 300 SOUTH WACKER DRIVE, SUITE 3200, CHICAGO, IL 60606. This firm appears frequently in patent prosecution.
  • Context: Internal reorganization / transfer between related corporate entities.
• 2021-04-02 (executed) / recorded 2021-04-02 — Reel 057221/0456
  • Conveyance: Assignment of Assignor's Interest
  • Assignor: VELOXIS PHARMACEUTICALS A/S
  • Assignee: VELOXIS PHARMACEUTICALS INC.
  • Correspondent: MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP, ATTN: PATENTS, 300 SOUTH WACKER DRIVE, SUITE 3200, CHICAGO, IL 60606. This is the same correspondent as the previous entry.
  • Context: Internal reorganization / transfer between related corporate entities.
• 2024-03-25 (executed) / recorded 2024-03-25 — Reel 063641/0080
  • Conveyance: Assignment of Assignors Interest (Inventors)
  • Assignor: LADEMANN, ANNE-MARIE; HOLM, PER; Gordon, Robert D
  • Assignee: LIFECYCLE PHARMA A/S
  • Correspondent: MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP, ATTN: PATENTS, 300 SOUTH WACKER DRIVE, SUITE 3200, CHICAGO, IL 60606. This is the same correspondent as previous entries.
  • Context: Inventor assignment to a corporate entity, likely part of an intellectual property restructuring.
• 2024-03-25 (executed) / recorded 2024-03-25 — Reel 063641/0081
  • Conveyance: Assignment of Assignors Interest (Inventor)
  • Assignor: NORLING, TOMAS
  • Assignee: LIFECYCLE PHARMA A/S
  • Correspondent: MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP, ATTN: PATENTS, 300 SOUTH WACKER DRIVE, SUITE 3200, CHICAGO, IL 60606. This is the same correspondent as previous entries.
  • Context: Inventor assignment to a corporate entity, likely part of an intellectual property restructuring.
• 2024-03-25 (executed) / recorded 2024-03-25 — Reel 063641/0082
  • Conveyance: Assignment of Assignors Interest
  • Assignor: LIFECYCLE PHARMA A/S
  • Assignee: VELOXIS PHARMACEUTICALS A/S
  • Correspondent: MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP, ATTN: PATENTS, 300 SOUTH WACKER DRIVE, SUITE 3200, CHICAGO, IL 60606. This is the same correspondent as previous entries.
  • Context: Internal corporate transfer between related entities.
• 2024-06-07 (executed) / recorded 2024-06-07 — Reel 063853/0762
  • Conveyance: Change of Address
  • Assignor: VELOXIS PHARMACEUTICALS INC.
  • Assignee: VELOXIS PHARMACEUTICALS INC.
  • Correspondent: MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP, ATTN: PATENTS, 300 SOUTH WACKER DRIVE, SUITE 3200, CHICAGO, IL 60606. This is the same correspondent as previous entries.
  • Context: Change of address for the assignee, not a change of ownership.

Timeline diagram

timeline
    title Ownership of US 11123331
    2020 : Filed by Veloxis Pharma Inc
    2021 : Veloxis Pharma A/S to Veloxis Pharma Inc
         : Veloxis Pharma A/S to Veloxis Pharma Inc
         : Issued
    2024 : Inventors to Lifecycle Pharma A/S
         : Lifecycle Pharma A/S to Veloxis Pharma A/S
         : Veloxis Pharma Inc change of address

NPE / troll-pattern signals

1. Shell-entity transfer — Not present. The transfers involve "Veloxis Pharmaceuticals Inc." and "Veloxis Pharmaceuticals A/S" and "Lifecycle Pharma A/S," all of which appear to be legitimate operating pharmaceutical entities related to the original assignee. No shell-like names (e.g., "IP Holdings") or addresses associated with registered agent services are observed.
2. Known asserter in the chain — Not present. None of the assignees (Veloxis Pharmaceuticals Inc., Veloxis Pharmaceuticals A/S, Lifecycle Pharma A/S) are recognized as known NPEs from public lists like RPX or Unified Patents.
3. Repeat correspondent across the chain — Present. MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP appears as the correspondent for all recorded assignments related to this patent (Reel 057199/0569, Reel 057221/0456, Reel 063641/0080, Reel 063641/0081, Reel 063641/0082, Reel 063853/0762). This firm is known for handling patent prosecution and general IP matters for various clients.
4. Cascading transfers — Not present. While there are multiple assignments in March 2021 and March 2024, they appear to be internal corporate restructuring or inventor assignments, not rapid consecutive transfers through unrelated entities. The 2024 transfers, specifically, occur on the same day (2024-03-25), indicating a coordinated internal transfer rather than cascading sales.
5. Pre-litigation transfer — Unclear. The Google Patents page indicates "Family has litigation," with cases filed in Delaware District Court starting in 2022 and 2024. The transfers to Lifecycle Pharma A/S and back to Veloxis Pharmaceuticals A/S occurred in March 2024 (Reel 063641/0080, 0081, 0082). If litigation for this specific patent was initiated immediately following these transfers, it could be a signal. However, without specific dates of complaint filing for this patent, it's unclear if the transfers directly precede assertion. The earliest reported litigation for the family is in 2022, which predates the 2024 assignments.
6. Bankruptcy fire-sale — Not present. There is no indication in the assignment records or the patent text that the original assignee, Veloxis Pharmaceuticals Inc., has undergone bankruptcy proceedings and sold its patents.
7. Privateering — Not present. There is no evidence suggesting Veloxis Pharmaceuticals Inc. (or its parent Asahi Kasei Pharma) is using an NPE to assert patents on its behalf. All transfers appear to be within related corporate entities.
8. Defensive aggregator (anti-NPE) — Not present. The chain does not terminate at any known defensive aggregators.

Verdict

Operating-company assertion

The assignment records show transfers primarily between Veloxis Pharmaceuticals A/S, Veloxis Pharmaceuticals Inc., and Lifecycle Pharma A/S, all of which appear to be related operating pharmaceutical companies. The continued presence of the same correspondent, MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP, across all recorded events (e.g., Reel 057199/0569, Reel 063641/0082), further suggests internal corporate management rather than external transfers to shell entities. Veloxis Pharmaceuticals Inc. is known to ship a product embodying the claims (Envarsus XR). While litigation is indicated for the patent family, the ownership chain itself does not exhibit strong NPE characteristics.

Verification link: USPTO Assignment Center Search for US11123331